DBV0 Stock Overview
A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
DBV Technologies S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.65 |
| 52 Week High | €2.88 |
| 52 Week Low | €0.60 |
| Beta | 0.87 |
| 11 Month Change | 2.53% |
| 3 Month Change | -27.68% |
| 1 Year Change | -77.18% |
| 33 Year Change | -92.50% |
| 5 Year Change | -96.50% |
| Change since IPO | -98.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| DBV0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.2% | 0.8% |
| 1Y | -77.2% | -16.0% | 6.1% |
Return vs Industry: DBV0 underperformed the German Biotechs industry which returned -16% over the past year.
Return vs Market: DBV0 underperformed the German Market which returned 6.1% over the past year.
Price Volatility
| DBV0 volatility | |
|---|---|
| DBV0 Average Weekly Movement | 14.8% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: DBV0's share price has been volatile over the past 3 months.
Volatility Over Time: DBV0's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 105 | Daniel Tassé | www.dbv-technologies.com |
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes.
DBV Technologies S.A. Fundamentals Summary
| DBV0 fundamental statistics | |
|---|---|
| Market cap | €78.72m |
| Earnings (TTM) | -€73.47m |
| Revenue (TTM) | €13.81m |
5.7x
P/S Ratio-1.1x
P/E RatioIs DBV0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DBV0 income statement (TTM) | |
|---|---|
| Revenue | US$14.94m |
| Cost of Revenue | US$0 |
| Gross Profit | US$14.94m |
| Other Expenses | US$94.45m |
| Earnings | -US$79.51m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.83 |
| Gross Margin | 100.00% |
| Net Profit Margin | -532.16% |
| Debt/Equity Ratio | 0% |
How did DBV0 perform over the long term?
See historical performance and comparison